Navigation Links
CV Therapeutics Reports 2008 First Quarter Financial Results
Date:4/25/2008

reement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Annual Report on From 10-K for the year ended December 31, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.

CV THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Amounts)

(Unaudited)

Three months ended

March 31,

2008 2007

Revenues:

Product sales, net $22,045 $11,989

Collaborative research 766 3,261

Total revenues 22,811 15,250

Costs and expenses:

Cost of sales 3,383 1,557

Research and development 17,245 27,178

Selling, general and administrative 32,450 42,448

Restructuring charges (7) -

Total costs and expenses 53,071 71,183

Loss from operations (30,260) (55,933)

Other income (expense), net:

Interest and other income, net 1,535 4,043

Interest expense (3,174) (3,166)

Total other income (expense), net
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... “Nature has developed, very cleverly, some ... desire in optical design,” said Joseph Shaw, director of ... we explore surfaces and structures at the nanoscale, we’ll ... in San Diego in August during a conference called ... chaired by Shaw and Rongguang Liang of the University ...
(Date:9/16/2014)... From cell phones to cars and flashlights, batteries ... and technology companies constantly are seeking ways to ... first time using a water-based solution, researchers at ... and more efficient nuclear battery that could be ... energy source in automobiles and also in complicated ...
(Date:9/16/2014)... CIRTEC Medical Systems’ Board of Directors has ... CIRTEC. , “I am delighted to be joining ... Brian Highley. “The company has made great strides improving ... over the past two years. The goal now is ... expand the services Cirtec offers its medical device customers.” ...
(Date:9/16/2014)... , Sept. 16, 2014  LABSCO, the ... and products to hospitals, physician office laboratories and ... effective October 1, 2014, it will serve as ... hospital market segments and as a semi-exclusive sales ... 48 contiguous United States . ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5LABSCO Secures Alliance With Siemens Healthcare Diagnostics 2LABSCO Secures Alliance With Siemens Healthcare Diagnostics 3
... Merrimack Pharmaceuticals, Inc. announced today that it ... therapeutic consisting of a mixture of three human ... irinotecan, at the 14th World Conference on Lung ... in Amsterdam, The Netherlands. (Logo: ...
... Dendreon Corporation (Nasdaq: DNDN ) today ... approved its Los Angeles cancer immunotherapy manufacturing facility, allowing ... PROVENGE ® (sipuleucel-T) across the U.S. to help ... symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.   ...
... Branch Fund: A Thisbe and Noah Scott Legacy, an ... announced its first funding award to Kevin Eggan, Ph.D., ... Harvard University.  The award will support Dr. Eggan,s ongoing ... affect it.  Dr. Eggan is a leading researcher in ...
Cached Biology Technology:Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 2FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 3FDA Approves Dendreon's Los Angeles Cancer Immunotherapy Manufacturing Facility 4The Olive Branch Fund Announces Funding Award to Harvard Researcher 2
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... diameter chunk of rock hit the Yukatan peninsula near the ... of 100 teratons of TNT. It left a crater more ... earthquakes and volcanism are widely accepted to have wiped out ... mammals. But what happened to the plants on which the ... the University of Arizona reveals that the meteorite impact that ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... The world,s leading conservation organizations have joined together to fight ... gorilla ( Gorilla beringei graueri ). Found only in ... of Congo (DRC), Grauer,s gorilla is not only the largest ... in the world. With their entire range consumed in ...
... and walked on two legs is considered to be one of ... to the far ends of the earth and the wonderful ... walk the way we walk. In the latest such search, ... have taken a closer look at bipedal kangaroos and wallabies and ...
... PA, March 13, 2013 Many Canadians are concerned ... sodium intake through a variety of measures, including lowering ... a national survey. The top barriers to limiting sodium ... processed foods and lower sodium restaurant menu options. ...
Cached Biology News:Gorillas caught in the crossfire in the DRC 2Gorillas caught in the crossfire in the DRC 3It's all in the way we move 2Canadians support interventions to reduce dietary salt 2
Cag-A (IgG) -Ab EIA Sample Size: 10 l...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
... Inhibitor is a recombinant protein that has been ... in the preparation of cDNA by reverse transcription, ... protein synthesis. RNA Safe Inhibitor tightly binds RNases ... range of eukaryotic RNases such as RNase A, ...
... and Recombinant RNasin Ribonuclease Inhibitors have broad ... of eukaryotic RNases of the neutral type ... effect by noncovalently binding to RNases in ... the binding of RNasin Ribonuclease Inhibitor to ...
Biology Products: